Disposal of own shares
Brussels (Belgium), 20 January 2020 – 20:05 (CET) – regulated information
Isabelle Ghellynck,
Investor Relations, UCB
T+32.2.559.9588, isabelle.ghellynck@ucb.com
In application of article 8:6 of the Royal Decree executing the new Belgian Code of Companies and Associations, UCB SA/NV announces that following exercises of stock options by its employees, it has disposed of UCB shares OTC in view of deliveries of shares to the relevant employees, within the framework of the Long Term Incentive Program of the UCB Group, as follows:
<img src="_up/ucb_com_presscenter/images/20200120_disposal_of_own_shares.png">
This press release is available on UCB SA/NV’s website via the following link.
Investor Relations
Antje Witte
Antje Witte
Investor Relations, UCB
T +32.2.559.94.14 antje.witte@ucb.com
T +32.2.559.94.14 antje.witte@ucb.com
Investor Relations, UCB
T+32.2.559.9588, isabelle.ghellynck@ucb.com
About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 7 500 people in approximately 40 countries, the company generated revenue of € 4.6 billion in 2018. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 7 500 people in approximately 40 countries, the company generated revenue of € 4.6 billion in 2018. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news
Asset Download
Stay up-to-date on the latest news and information from UCB